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A Hungarian soldier previously immunized against Neisseria meningitidis by
quadrivalent polysaccharide vaccine was twice infected with meningococci within six
weeks. The patient was treated with ceftriaxone during both episodes and he
successfully recovered. His close contacts received rifampicin prophylaxis. An
investigation was performed to characterize the genetic background of the pathogens
to ascertain if the recurrent invasive meningococcal disease was caused by the same
strain and to ﬁnd out the reason for reinfection. Both meningococci belonged to the
ﬁne type Y:P1.5-2,10-1:F4-1:ST-23. This is the ﬁrst description of the Europe-wide
prevalent N. meningitidis serogroup Y in Hungary. In the ﬁrst episode, we found wild-
type rpoB allele in the non-culturable sample implying the susceptibility to rifampicin.
The culturable isolate from the second episode proved resistant to rifampicin and had a
point mutation in the rpoB gene. The rifampicin resistance might have evolved during
the prophylactic treatment of contacts. Previous immunization of the patient with
polysaccharide vaccine was ineffective due to his immunodeﬁciency, thus immuni-
zation with conjugate vaccine was proposed. We have proposed the implementation of
centralized rifampicin susceptibility testing of N. meningitidis strains within a deﬁned
time frame to intervene and administer appropriate prophylaxis to close contacts.
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Introduction
In Hungary, invasive meningococcal disease (IMD) is mandatorily
notiﬁable and it is recommended to submit Neisseria meningitidis isolates or
clinical samples – in case of non-culturable samples – for conﬁrmation and
molecular typing to the IMD National Reference Laboratory (NRL) of National
Center for Epidemiology (NCE).
The incidence of IMD in Hungary varies between 0.17 and 1.00 notiﬁed
cases per 100,000 population (mean 0.41/100,000) from 1988 to 2013 (Figure 1).
In 2011, the notiﬁcation rate was 0.67 cases per 100,000 population which is
below the total European notiﬁcation rate (0.77 cases per 100,000 population) [1].
However, the case fatality rate of IMD was higher (17.9%) than the European
average (8.7%) in 2011 [1].
According to the NRL data, serogroups B and C caused the most cases of
IMD and serogroup B was most prevalent (average 74% of known serogroups/
year, 1988–2013) (Figure 1) in Hungary. During this period, there were two
epidemiological seasons (1999/2000 and 2010/2011) when serogroup C was
reported in a higher proportion than serogroup B due to two outbreaks among
soldiers and high school students, respectively (unpublished data, source:
Surveillance of IMD, National Center for Epidemiology, Hungary).
Figure 1. Notiﬁcation rate of invasive meningococcal disease by serogroup in Hungary, 1988–2013
(Source: Surveillance of IMD, National Center for Epidemiology, Hungary)
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Although, the proportion of N. meningitidis serogroup Y (NmY) is increas-
ing among notiﬁed IMD cases in Europe [2], in Hungary the ﬁrst NmY IMD case
was conﬁrmed in 2013 which is presented here as a case report.
Case Report
A 24-year-old male patient was hospitalized with clinical suspicion of
meningococcal meningitis to the Department of Infectious Diseases No. III in
Szent Lászlo´ Hospital, Budapest on 15 October 2013. He was a professional
soldier with an unremarkable medical history and no regular medications. Because
he repeatedly joined in military missions, he was immunized with quadrivalent
(A, C, Y, W) meningococcal polysaccharide vaccine, 4 years and 1 year prior to
the onset of symptoms, respectively.
He was admitted to the department with a one-day history of headache,
fever, vomiting, and exanthemas. During the examination he appeared ill,
psychometrically agitated, presented with stiffness of the neck and petechiae and
purpura were observed on the torso and extremities. His body temperature was
37.2 °C, blood pressure was 116/70 mmHg, pulse rate was 85 beats/min. The
patient didn’t show any focal neurological signs and he was not disorientated.
Cranial CT scan without the administration of contrast material revealed no
evidence of acute intracranial haemorrhage, territorial infarction, or intracranial
mass lesion. Lumbar puncture was performed, the cerebrospinal ﬂuid (CSF) was
purulent and microscopy revealed Gram-negative diplococci in the CSF smear. No
bacteria grew from the CSF and the agglutination test by Wellcogen kit was
negative for N. meningitidis and Streptococcus pneumoniae. The CSF sample was
sent to the NCE to conﬁrm the suspicion of IMD. For detection of the meningo-
coccal DNA in CSF, Real Time, and conventional PCRs using species (target gene
ctrA) and serogroup speciﬁc (siaDWY, siaDB, siaDC) primers were performed
[3, 4]. The CSF sample proved to be positive for serogroup Y meningococcus.
Immediately after admission of the patient, ceftriaxone (2 × 2g/day) was given and
continued for 10 days. After 10 days in hospital care, he recovered without any
complications and was discharged home. Investigation and management of
contacts was initiated by the NCE and performed by local authorities within
24 h after raising the suspicion of IMD. Based on the results of contact tracing the
patient had been visiting his girlfriend and her family at the time of onset of
the symptoms. These ﬁve adult family members and additional eight health care
workers were given rifampicin (2 × 600 mg for 2 days) according to the Hungarian
guideline for management of IMD [5]. The patient participated in military training
before visiting his girlfriend; therefore, additional contact tracing was performed
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by both the Hungarian Defence Forces and Public Health and Epidemiological
Service. Thirty soldiers identiﬁed as close contacts were given ciproﬂoxacin
(2 × 500 mg) as prophylaxis. During the incubation period, no symptoms were
observed among close contacts.
Six weeks later, the same patient was readmitted to the same hospital with a
one-day history of fever, sore throat, mild headache, and exanthemas. Apart from
these symptoms, he was in good condition, the body temperature was normal,
blood pressure was 150/80 mm Hg, and pulse rate was 103 beats/min. On
examination, he was alert and orientated, no focal neurological signs nor neck
stiffness were present. There were maculopapular exanthemas on the extremities
with a few purpura and petechia. Ceftriaxone (2 × 2g/day) was administered and
continued again for 10 days, then the patient was discharged in a good condition.
N. meningitidis was cultured from blood culture taken before commencing
antibiotic therapy. At the NCE, the isolate was phenotyped using slide agglutina-
tion with monoclonal antisera (Remel Europe, England) and antibiotic suscepti-
bility was determined by use of gradient minimal inhibitory concentration
(MIC) tests (Lioﬁlchem, Italy) and interpreted according to the EUCAST guide-
lines [6]. The causative agent was again NmY with the following MIC values:
penicillin, 0.064 mg/L; ceftriaxone, 0.002 mg/L; ciproﬂoxacin, 0.016 mg/L; and
rifampicin, >32 mg/L.
Based on the second epidemiological investigation of close contacts, one
family member and ﬁve healthcare workers were given rifampicin (2 × 600 mg for
2 days) prophylaxis. Furthermore, 165 soldiers were given 2 × 500 mg ciproﬂox-
acin according to the recommendation of the Hungarian Defence Forces, Public
Health and Epidemiological Service. During the second episode, one soldier
contact showed upper respiratory symptoms and he was observed for 10 days. No
IMD developed.
Meningococci with identical serogroup – detected in Hungary for the ﬁrst
time – suggested that the two episodes may have been related to each other and the
suspected recurrent infection probably due to the immunodeﬁcient status of the
patient. Moreover, the detected rifampicin resistance could imply unsuccessful
antibiotic prophylaxis of contacts who had taken rifampicin during the ﬁrst
episode and the strain persisted in symptomless carriers.
Therefore, an investigation was performed to characterize the genetic
background of the pathogens in order to ascertain if the recurrent IMD was
caused by the same pathogen and to determine the cause of the suspected
reinfection.
The pathogens from both episodes were characterized by multilocus
sequence typing and sequencing of variable regions of porA and fetA genes
(called ﬁne typing) according to the recommendation of the European
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Meningococcal Disease Society [7]. The presence of mutations associated with
rifampicin resistance in speciﬁc region of rpoB gene, encoding the β subunit of
bacterial RNA polymerase was investigated by sequencing [8]. Due to the
recurrent IMD, diagnostic tests for immunodeﬁciency were performed [9].
Both meningococci belonged to the serogroup Y, sequence type ST-23
(ST-23 complex/Cluster A3) and had identical ﬁne type (Y:P1.5-2,10-1:F4-1). In
the ﬁrst episode, wild-type rpoB allele implying susceptibility to rifampicin of the
pathogen was found. The isolate from the second episode had a point mutation at
amino acid residue S557 (S557F) in the rpoB gene associated with high level
rifampicin resistance [8]. The patient was screened for terminal complement
component defects, and C8 component absence was revealed. Testing for HIV
antibodies was negative. Immunization with conjugate vaccine was proposed for
the patient to prevent him from developing new IMD in the future.
Discussion
During the last 10 years, NmY has increased importance in Europe [1]. In
2010 and 2011, the highest relative proportion of NmY IMD among all serogroups
was reported by Scandinavian countries (up to 55%), followed by the
central/western European countries (5%–10%) but no NmY IMD was detected
in Hungary [2]. To our best knowledge, this is the ﬁrst report on a NmY pathogen
that belonged to Y:P1.5-2,10-1:F4-1:ST23 type in Hungary. According to the data
of the European Meningococcal Epidemiology in Real Time (EMERT) database,
that has collected molecular typing data for N. meningitidis in Europe since 2007,
this particular type was the most prevalent among reported types of NmY strains
[10]. This sequence-based typing method gives opportunity to evaluate the
probable relationship between two or more strains, even if it is a non-culturable
pathogen. The ﬁne types of our both meningococci were identical which suggested
that the recurrence of IMD with the same strain was highly likely.
The C8 component absence in terminal complement pathways can explain
the recurrence of the IMD [11], and the ineffectiveness of polysaccharide vaccine
for NmY [12] also. In case of complement deﬁciency immunization with conju-
gate vaccine is the gold standard preventive measure against IMD in line with
international recommendation [13].
Many European countries including Hungary recommend rifampicin as ﬁrst
choice for prophylaxis. Rifampicin resistance is rare in Europe but several studies
have observed the emergence and spread of rifampicin-resistant strains among
carriers after prophylaxis [14]. Similarly, in the second IMD episode the resistance
probably evolved during the prophylactic treatment of contacts. On this occasion,
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six contacts were given rifampicin prophylaxis since the administration of the drug
was delivered immediately after the notiﬁcation of IMD and rifampicin resistance
was conﬁrmed only several days later at the NCE. By the time this ﬁnding became
known, the contacts had ﬁnished the prophylactic therapy and the 10-day
incubation period had been passed [15]. Due to the low IMD incidence in
Hungary determination of rifampicin MIC value is a rarely requested test and
is not available within several diagnostic laboratories in Hungary.
Considering that in the last 5 years no rifampicin resistance was observed
among culturable meningococci isolates in Hungary, the emergence of rifampicin
resistance is of concern. Therefore, we have proposed the implementation of
centralized rifampicin susceptibility testing of N. meningitidis strains at the NCE
within a deﬁned time frame of 4–8 days in order to intervene and administer
appropriate prophylaxis to close contacts if a resistant strain is detected. The
implementation of the proposed modiﬁcations could improve the effectiveness of
meningococcal public health management.
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